Table 1. Estimated vaccination coverage by age 24 months* among children born during 2013–2016 for selected vaccines and doses — National Immunization Survey-Child, United States, 2014–2018
Vaccine/Dose |
% (95% CI) |
Birth years† |
Difference (2013–2014) to (2015–2016) |
2013–2014 |
2015–2016 |
DTaP§ |
≥3 doses |
93.6 (93.0 to 94.2) |
93.8 (93.1 to 94.5) |
0.2 (-0.7 to 1.1) |
≥4 doses |
80.6 (79.7 to 81.6) |
80.3 (79.0 to 81.5) |
-0.4 (-1.9 to 1.2) |
Poliovirus (≥3 doses) |
91.7 (91.0 to 92.4) |
92.7 (92.0 to 93.4) |
1.0 (0.0 to 2.0) |
MMR (≥1 dose) ¶ |
90.0 (89.3 to 90.7) |
90.4 (89.5 to 91.2) |
0.3 (-0.8 to 1.5) |
Hib** |
Primary series |
92.7 (92.1 to 93.3) |
92.7 (91.8 to 93.5) |
0.0 (-1.1 to 1.0) |
Full series |
80.2 (79.3 to 81.1) |
79.6 (78.3 to 80.9) |
-0.6 (-2.1 to 1.0) |
HepB |
Birth dose†† |
71.8 (70.7 to 72.8) |
75.0 (73.7 to 76.2) |
3.2 (1.6 to 4.9)§§ |
≥3 doses |
90.9 (90.2 to 91.6) |
91.0 (90.2 to 91.9) |
0.1 (-1.0 to 1.2) |
Varicella (≥1 dose) ¶ |
89.3 (88.6 to 90.1) |
90.0 (89.1 to 90.9) |
0.7 (-0.5 to 1.8) |
PCV |
≥3 doses |
91.9 (91.2 to 92.5) |
92.0 (91.1 to 92.8) |
0.1 (-1.0 to 1.2) |
≥4 doses |
81.5 (80.6 to 82.4) |
81.0 (79.8 to 82.3) |
-0.4 (-2.0 to 1.1) |
HepA |
≥1 dose |
83.2 (82.4 to 84.1) |
84.7 (83.6 to 85.8) |
1.5 (0.1 to 2.9)§§ |
≥2 doses (by 35 months) |
74.0 (72.8 to 75.3) |
76.6 (74.7 to 78.4) |
2.6 (0.4 to 4.8)§§ |
Rotavirus (by 8 months)¶¶ |
72.4 (71.3 to 73.4) |
73.6 (72.2 to 74.9) |
1.2 (-0.5 to 2.9) |
Influenza (≥2 doses)*** |
53.0 (51.9 to 54.1) |
56.6 (55.2 to 58.0) |
3.6 (1.8 to 5.4)§§ |
Combined 7-vaccine series††† |
68.4 (67.3 to 69.5) |
68.5 (67.1 to 69.9) |
0.1 (-1.7 to 1.9) |
No vaccinations |
1.1 (1.0 to 1.3) |
1.3 (1.1 to 1.5) |
0.1 (-0.2 to 0.4) |
Abbreviations: CI = confidence interval; DTaP = diphtheria, tetanus toxoids, and acellular pertussis vaccine; HepA = hepatitis A vaccine; HepB = hepatitis B vaccine; Hib = Haemophilus influenzae type b conjugate vaccine; MMR = measles, mumps, and rubella vaccine; PCV = pneumococcal conjugate vaccine.
* Includes vaccinations received by age 24 months (before the day the child turns 24 months), except for the HepB birth dose, rotavirus vaccination, and ≥2 HepA doses by 35 months. For all vaccines, except the HepB birth dose and rotavirus vaccination, the Kaplan-Meier method was used to estimate vaccination coverage to account for children whose vaccination history was ascertained before age 24 months (35 months for ≥2 HepA doses).
† Data for the 2013 birth year are from survey years 2014, 2015, and 2016; data for the 2014 birth year are from survey years 2015, 2016, and 2017; data for the 2015 birth year are from survey years 2016, 2017, and 2018; data for the 2016 birth year are considered preliminary and come from survey years 2017 and 2018 (data from survey year 2019 are not yet available).
§ Includes children who might have received diphtheria and tetanus toxoids vaccine or diphtheria, tetanus toxoids, and pertussis vaccine.
¶ Includes children who might have received measles, mumps, rubella, and varicella combination vaccine.
** Hib primary series: receipt of ≥2 or ≥3 doses, depending on product type received; full series: primary series and booster dose, which includes receipt of ≥3 or ≥4 doses, depending on product type received.
†† One dose HepB administered from birth through age 3 days.
§§ Statistically significantly different from 0 at p<0.05.
¶¶ Includes ≥2 doses of Rotarix monovalent rotavirus vaccine, or ≥3 doses of RotaTeq pentavalent rotavirus vaccine. The maximum age for the final rotavirus dose is 8 months, 0 days.
*** Doses must be at least 24 days apart (4 weeks with a 4-day grace period).
††† The combined 7-vaccine series (4:3:1:3*:3:1:4) includes ≥4 doses of DTaP, ≥3 doses of poliovirus vaccine, ≥1 dose of measles-containing vaccine, the full series of Hib (≥3 or ≥4 doses, depending on product type), ≥3 doses of HepB, ≥1 dose of varicella vaccine, and ≥4 doses of PCV.
Comments